New York Rexulti Attorneys
In July 2015, Otsuka Pharmaceuticals received FDA approval for their new drug, Rexulti, an antipsychotic similar to Abilify. Abilify was previously found to cause extreme compulsive behaviors in users. The FDA approved Rexulti based on two clinical trials that evaluated the efficacy of the drug in Schizophrenic participants, as well as participants with Major Depressive Disorder. Both trials demonstrated fewer symptoms in Rexulti users than Abilify users. As a second-generation version of Abilify, Rexulti was meant to improve the clinical profile of the drug by causing fewer side effects. However, Rexulti had only a slight chemical distinction from Abilify, and shares a very similar chemical structure.
Serving Clients Nationwide
Rexulti Causing Compulsive Behaviors
One of the major side effects of Abilify is extreme compulsive behaviors, like gambling. Although a gambling warning was stated in the Rexulti product monograph, it was not listed in the medication guide for patients, or on the official website. This concealment of undesirable warnings or information from the public resulted in a number of reports of gambling by users of Rexulti. Due to the failure to warn, users were unaware of this possible side effect.
Expected complications associated with Rexulti include weight gain, sense of restlessness, and an increase in suicidal thought and behaviors among children and teens. Unexpected complications, such as impulse-control disorders, have also resulted from the use of this new drug. Like Abilify users, Rexulti users were reported experiencing compulsive behaviors, including pathological gambling and hyper-sexuality. The compulsive behaviors were prominent in users especially when the drug is taken with other antipsychotics with partial agonist activity at the dopamine receptors. Rexulti users with a history of impulse control disorders are at an even greater risk of experiencing these behaviors.
Researchers have found evidence suggesting excessive amounts of the neurotransmitters, dopamine and serotonin, trigger excessive compulsions leading to pathological gambling, hyper-sexuality, over-shopping, and even binge eating. These behaviors can have devastating emotional and financial consequences as users will do almost anything to continue their compulsive activity.
Have You Been Injured as a Result of Rexulti Use?
Rheingold Giuffra Ruffo & Plotkin LLP is currently investigating claims on behalf of injured users, as our firm has over 30 years of experience handling dangerous drugs cases. If you or someone you know has suffered from compulsive gambling, hyper-sexuality or other compulsive behaviors due to taking Rexulti, our New York defective drug attorneys at Rheingold Giuffra Ruffo & Plotkin LLP can help you fight to protect your rights. We take pride in helping people from across the nation with their most critical legal problems. Our New York dangerous drug attorneys provide clients with personal attention and guidance as they navigate through this stressful time.
Schedule an initial and free consultation with a member of our firm. Call (888)260-0473 today.
Auto Accident $2,750,000
Biopsy Resulting In Blindness $2,500,000
Birth Injury $1,000,000
Brain Damage $12,000,000
Brain Damage of Infant $1,000,000
Brain Damage of Infant $2,100,000
Cancer Misdiagnosis $2,500,000
Cardiovascular Injury $2,200,000
Cataract Surgery Complication $1,700,000
Child's Hand Injury $9,000,000